Evidence map›Paper›PMID 19436644›Full record

ReviewVascular health and risk management2009

Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review.

Steve Fordan, Philip Raskin

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vascular health and risk management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Steve FordanDepartment of Medicine, Division of Endocrinology, University of Texas, Southwestern Medical Center, Dallas, TX 75390-8858, USA.
Philip Raskin
The University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The insulin analogs lispro, aspart, and glulisine are the only commercially available rapid-acting insulins to treat diabetes. We review the evidence for treating hyperglycemia, using insulin, and specifically using rapid-acting analogs in diabetic individuals, on the prevention of vascular events. We review the beneficial effects of insulin on the vascular system, which include vasodilation and anti-inflammatory actions. The effects of treating hyperglycemia and intensive blood glucose control on vascular outcomes are reviewed.

Indexed as

Anti-Inflammatory AgentsBlood GlucoseDiabetes MellitusDiabetic AngiopathiesGlycated HemoglobinHumansHypoglycemic AgentsInsulinInsulin AspartInsulin LisproPostprandial PeriodTreatment OutcomeVasodilator AgentsAnti-Inflammatory AgentsBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinInsulin Aspartinsulin glulisineInsulin LisproVasodilator Agentsaspartglulisinelispronitric oxide synthetasenuclear factor kappa B

Identifiers

PMID19436644
PMCPMC2672433
OpenAlexW1979799113

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.